EnGene Holdings Valuation
| ENGN Etf | USD 8.69 0.08 0.91% |
At this time, the entity appears to be undervalued. enGene Holdings Common shows a prevailing Real Value of $11.89 per share. The current price of the entity is $8.69. Our model computes the value of enGene Holdings Common from inspecting the entity fundamentals such as shares outstanding of 50.98 M, and Return On Equity of -1.23 as well as reviewing its technical indicators and probability of bankruptcy.
Price Book 1.9144 | Enterprise Value 208.1 M | Enterprise Value Ebitda (6.01) |
Undervalued
Today
Please note that EnGene Holdings' price fluctuation is somewhat reliable at this time. Calculation of the real value of enGene Holdings Common is based on 3 months time horizon. Increasing EnGene Holdings' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since EnGene Holdings is currently traded on the exchange, buyers and sellers on that exchange determine the market value of EnGene Etf. However, EnGene Holdings' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.69 | Real 11.89 | Target 35.5 | Hype 9.17 | Naive 10.59 |
The intrinsic value of EnGene Holdings' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence EnGene Holdings' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of enGene Holdings Common helps investors to forecast how EnGene etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of EnGene Holdings more accurately as focusing exclusively on EnGene Holdings' fundamentals will not take into account other important factors: EnGene Holdings Total Value Analysis
enGene Holdings Common is currently forecasted to have valuation of 208.13 M with market capitalization of 440.95 M, debt of 9.78 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the EnGene Holdings fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
208.13 M | 440.95 M | 9.78 M |
EnGene Holdings Asset Utilization
One of the ways to look at asset utilization of EnGene is to check how much profit was generated for every dollar of assets it reports. enGene Holdings Common shows a negative utilization of assets of -0.22 percent, losing $0.002207 for each dollar of assets held by the entity. Inefficient asset utilization denotes the company is being less efficient with each dollar of assets it shows. Put another way, asset utilization of enGene Holdings Common shows how inadequate it operates for each dollar spent on its assets.EnGene Holdings Ownership Allocation
EnGene Holdings holds a total of 50.98 Million outstanding shares. The majority of enGene Holdings Common outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in enGene Holdings Common to benefit from reduced commissions. Accordingly, institutional investors are subject to a different set of regulations than regular investors in EnGene Holdings. Please pay attention to any change in the institutional holdings of enGene Holdings Common as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.EnGene Holdings Profitability Analysis
Net Loss for the year was (99.92 M) with profit before overhead, payroll, taxes, and interest of 0.About EnGene Holdings Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of enGene Holdings Common. In general, an absolute valuation paradigm, as applied to this etf, attempts to find the value of enGene Holdings Common based exclusively on its fundamental and basic technical indicators. By analyzing EnGene Holdings's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of EnGene Holdings's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of EnGene Holdings. We calculate exposure to EnGene Holdings's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of EnGene Holdings's related companies.EnGene Holdings Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 23.2 M |
Other Information on Investing in EnGene Etf
EnGene Holdings financial ratios help investors to determine whether EnGene Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EnGene with respect to the benefits of owning EnGene Holdings security.